Harnessing the human microbiome: Probiotic and prebiotic interventions to reduce hospital-acquired infections and enhance immunity

Aliu Olalekan Olatunji, Janet Aderonke Olaboye, Chukwudi Cosmos Maha, Tolulope Olagoke Kolawole, Samira Abdul
{"title":"Harnessing the human microbiome: Probiotic and prebiotic interventions to reduce hospital-acquired infections and enhance immunity","authors":"Aliu Olalekan Olatunji, Janet Aderonke Olaboye, Chukwudi Cosmos Maha, Tolulope Olagoke Kolawole, Samira Abdul","doi":"10.51594/imsrj.v4i7.1356","DOIUrl":null,"url":null,"abstract":" Hospital-acquired infections (HAIs) represent a significant burden on healthcare systems, leading to increased morbidity, mortality, and healthcare costs. Recent advancements in microbiome research have highlighted the potential of probiotic and prebiotic interventions to mitigate HAIs and bolster immunity. This review explores the role of the human microbiome in health and disease, focusing on the promising strategies of utilizing probiotics and prebiotics to reduce HAIs. Probiotics, comprising live beneficial bacteria, can restore and maintain a balanced gut microbiota, potentially outcompeting pathogenic organisms and enhancing host immune responses. Prebiotics, however, are non-digestible food ingredients that selectively stimulate the growth and activity of beneficial bacteria in the gut. The synergistic effects of probiotics and prebiotics, known as symbiotic, offer an even greater potential for clinical application. Numerous studies have demonstrated the efficacy of specific probiotic strains, such as Lactobacillus and Bifidobacterium, in preventing infections and modulating immune functions. Furthermore, prebiotics like fructo-oligosaccharides (FOS) and galacto-oligosaccharides (GOS) have shown to enhance the growth of probiotic bacteria, thus providing a twofold protective mechanism. The integration of these interventions into clinical practice could revolutionize the prevention and management of HAIs, reducing the reliance on antibiotics and mitigating the risk of antimicrobial resistance. However, challenges such as strain-specific effects, dosage optimization, and individual variability need to be addressed through rigorous clinical trials. This review underscores the need for further research and clinical validation to harness the full potential of the human microbiome in combating HAIs and enhancing patient outcomes through probiotic and prebiotic interventions. \nKeywords:  Human Microbiome, HAIs, Immunity.","PeriodicalId":508118,"journal":{"name":"International Medical Science Research Journal","volume":"24 25","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2024-07-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"International Medical Science Research Journal","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.51594/imsrj.v4i7.1356","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

 Hospital-acquired infections (HAIs) represent a significant burden on healthcare systems, leading to increased morbidity, mortality, and healthcare costs. Recent advancements in microbiome research have highlighted the potential of probiotic and prebiotic interventions to mitigate HAIs and bolster immunity. This review explores the role of the human microbiome in health and disease, focusing on the promising strategies of utilizing probiotics and prebiotics to reduce HAIs. Probiotics, comprising live beneficial bacteria, can restore and maintain a balanced gut microbiota, potentially outcompeting pathogenic organisms and enhancing host immune responses. Prebiotics, however, are non-digestible food ingredients that selectively stimulate the growth and activity of beneficial bacteria in the gut. The synergistic effects of probiotics and prebiotics, known as symbiotic, offer an even greater potential for clinical application. Numerous studies have demonstrated the efficacy of specific probiotic strains, such as Lactobacillus and Bifidobacterium, in preventing infections and modulating immune functions. Furthermore, prebiotics like fructo-oligosaccharides (FOS) and galacto-oligosaccharides (GOS) have shown to enhance the growth of probiotic bacteria, thus providing a twofold protective mechanism. The integration of these interventions into clinical practice could revolutionize the prevention and management of HAIs, reducing the reliance on antibiotics and mitigating the risk of antimicrobial resistance. However, challenges such as strain-specific effects, dosage optimization, and individual variability need to be addressed through rigorous clinical trials. This review underscores the need for further research and clinical validation to harness the full potential of the human microbiome in combating HAIs and enhancing patient outcomes through probiotic and prebiotic interventions. Keywords:  Human Microbiome, HAIs, Immunity.
利用人体微生物组:益生菌和益生元干预措施,减少医院感染并增强免疫力
医院获得性感染(HAIs)给医疗保健系统带来了沉重负担,导致发病率、死亡率和医疗保健成本增加。微生物组研究的最新进展突显了益生菌和益生元干预措施在减轻 HAIs 和增强免疫力方面的潜力。本综述探讨了人类微生物组在健康和疾病中的作用,重点是利用益生菌和益生元减少 HAIs 的可行策略。益生菌由活的有益细菌组成,可以恢复和维持肠道微生物群的平衡,从而有可能战胜致病微生物并增强宿主的免疫反应。而益生元是一种不可消化的食物成分,可选择性地刺激肠道中有益细菌的生长和活性。益生菌和益生元的协同作用被称为 "共生",为临床应用提供了更大的潜力。大量研究表明,乳酸杆菌和双歧杆菌等特定益生菌株在预防感染和调节免疫功能方面具有功效。此外,果寡糖(FOS)和半乳糖寡糖(GOS)等益生元也能促进益生菌的生长,从而提供双重保护机制。将这些干预措施纳入临床实践可彻底改变 HAIs 的预防和管理,减少对抗生素的依赖,降低抗菌素耐药性的风险。然而,菌株特异性效应、剂量优化和个体差异等挑战需要通过严格的临床试验来解决。本综述强调了进一步研究和临床验证的必要性,以充分发挥人类微生物组的潜力,通过益生菌和益生元干预措施抗击 HAIs 并改善患者预后。关键词 人类微生物组 HAIs 免疫力
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信